

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Alzheimer's Disease – From Fundamental Insights to Light at the End of the Translational Tunnel (Q8)

Scientific Organizers: John Q. Trojanowski, Charles F. Albright and Hui Zheng

Parkinson's Disease: Genetics, Mechanisms and Therapeutics (Q7)

Scientific Organizers: Patrick A. Lewis, Thomas Gasser and Marcel P. van der Brug

March 2-7, 2014 • Keystone Resort • Keystone, Colorado, USA

Abstract & Scholarship Deadline: November 5, 2013 / Abstract Deadline: December 5, 2013 / Discounted Registration Deadline: January 8, 2014

SUNDAY, MARCH 2

MONDAY, MARCH 3

Keynote Address (Joint)

Michel Goedert, Medical Research Council, UK
AD and PD are Protein Misfolding Diseases

Phenotypic and Genotypic Complexity of AD and PD (Joint)

Andrew B. Singleton, NIA, National Institutes of Health, USA
Genetics of AD and PD

Dennis W. Dickson, Mayo Clinic, USA
Pathological Overlap of AD and PD

Ryan J. Watts, Genentech, Inc., USA
Study of Crenezumab, an Anti-Aβ Antibody, in Early Alzheimer's Disease

Short Talk(s) Chosen from Abstracts

Genome Wide Association and PD (Q7)

Thomas Gasser, University of Tübingen, Germany
GWA Studies and PD - New Pathways and Old Targets

Vincent Plagnol, UCL Genetics Institute, UK
Deciphering the Role of LRRK2 in Genome Wide Susceptibility to PD

Haydeh Payami, Wadsworth Center, New York State Department of Health, USA
Interaction between Genes and Environment in PD

Short Talk Chosen from Abstracts

Genetics of AD (Q8)

Christine Van Broeckhoven, Neurodegenerative Brain Diseases Group, VIB and University of Antwerp, Belgium
Genetics of Familial AD

Richard Mayeux, Columbia University, USA
Genetics of Late Onset AD

Gerard D. Schellenberg, University of Pennsylvania, USA
New AD Risk Factor Genes from GWAS

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, MARCH 4

Biomarkers of AD and PD (Joint)

Ronald C. Petersen, Mayo Clinic, USA
Temporal Ordering of AD Biomarkers Based on ADNI Data

Kenneth L. Marek, Institute for Neurodegenerative Disorders, USA
Parkinson Progression Marker Initiative

Kaj Blennow, University of Gothenburg, Sweden
CSF Biomarkers for AD: Approaching the End of the Long Road to Validated and Approved Biomarkers

Thomas J. Montine, University of Washington Medical Center, USA
CSF and Proteomic Studies of AD and PD Biomarkers

Short Talk(s) Chosen from Abstracts

Mitochondrial Biology and the Pathology of PD (Q7)

Richard J. Youle, NINDS, National Institutes of Health, USA
Mitophagy and the Etiology of Parkinsonism

Helene Marie Plun-Favreau, University College London Institute of Neurology, UK
Novel Players in Mitochondrial Quality Control and Genetic PD

Alex J. Whitworth, University of Sheffield, UK
Young Onset PD - Lessons from Drosophila

Short Talk Chosen from Abstracts

AD Biomarkers (Q8)

Daniel M. Skovronsky, Avid Radiopharmaceuticals, Inc., USA
Amyloid Imaging

Clifford R. Jack, Mayo Clinic, USA
MRI of AD

David M. Holtzman, Washington University, USA
CSF Biomarkers and Sleep Biomarkers as Diagnostic and Prognostic Factors in Preclinical Alzheimers' Disease

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, MARCH 5

What Are The Toxic Species of Tau, Aβ and α-Synuclein (Joint)

Karen Hsiao Ashe, University of Minnesota, USA
Toxic Species of Tau and Aβ

Dennis J. Selkoe, Harvard Medical School, USA
Protein Misfolding in Alzheimer's and Parkinson's Disease: New Mechanistic Insights

Susan Lindquist, HHMI/Whitehead Institute for Biomedical Research, USA
Toxic Species of α-Synuclein

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Alzheimer's Disease – From Fundamental Insights to Light at the End of the Translational Tunnel (Q8)

Scientific Organizers: John Q. Trojanowski, Charles F. Albright and Hui Zheng

Parkinson's Disease: Genetics, Mechanisms and Therapeutics (Q7)

Scientific Organizers: Patrick A. Lewis, Thomas Gasser and Marcel P. van der Brug

March 2-7, 2014 • Keystone Resort • Keystone, Colorado, USA

Abstract & Scholarship Deadline: November 5, 2013 / Abstract Deadline: December 5, 2013 / Discounted Registration Deadline: January 8, 2014

Hilal A. Lashuel, Swiss Federal Institute of Technology, Switzerland
Toxic Species of alpha-Synuclein

Short Talk(s) Chosen from Abstracts

Pluripotent Stem Cells and Inherited PD (Q7)

Tilo Kunath, University of Edinburgh, UK
alpha-Synuclein Dysfunction in Pluripotent Stem Cell Derived Neuronal Cells

Speakers to be Announced

Short Talk Chosen from Abstracts

Transmission of Tau and Abeta (Q8)

John Q. Trojanowski, University of Pennsylvania, USA
Transmission of tau Pathology with Synthetic tau Fibrils in tau Tg Mice

Virginia M. Y. Lee, University of Pennsylvania School of Medicine, USA
Transmission of alpha-Synuclein

Karen Duff, Columbia University, USA
Transmission of Tau

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, MARCH 6

Passive Immunization and Other Novel Therapies to Treat AD and PD (Joint)

Eliezer Masliah, University of California, San Diego, USA
Passive Immunization to Treat PD

Kurt R. Brunden, University of Pennsylvania, USA
Microtubule Stabilizing Drugs to Treat Axonal Transport Failure in AD and PD

David S. Bredt, Janssen, USA
"Translating Alzheimer's disease science into breakthrough therapies".

Michael Hutton, Eli Lilly Research Center, UK
Passive Immunization to Treat AD

Short Talk(s) Chosen from Abstracts

LRRK2 Biology and PD Therapeutics (Q7)

Mark Cookson, NIA, National Institutes of Health, USA
State-of-the-Protein on LRRK2 Biology

Alastair D. Reith, GlaxoSmithKline Medicines Research, UK
Industry Viewpoint on Targeting LRRK2

Nathanael Gray†, Dana-Farber Cancer Center, USA
Academic Viewpoint on Targeting LRRK2

Alfred Wittinghofer, Max Planck Institut, Germany
Structural Studies on Roco Proteins and Implications for LRRK2

AD Prevention Versus Intervention Trials (Q8)

Reisa A. Sperling, Brigham & Women's Hospital, Harvard Medical School, USA

Sporadic AD Prevention Trials

Speaker to be Announced

Mark S. Forman, Merck, USA
BACE Inhibitors for AD Intervention and Prevention

Short Talk Chosen from Abstracts

FRIDAY, MARCH 7